Statins and a GLP-1: Taking Lipitor or Crestor With Ozempic or Mounjaro

A statin and a GLP‑1 can be taken together, and in the trials that proved these drugs protect the heart, most people did exactly that. Nine in ten people in SELECT, the Wegovy heart trial, were already on cholesterol-lowering treatment. When semaglutide was tested directly with atorvastatin (Lipitor), total exposure to the statin did not change; only its peak came lower and later. Oral semaglutide raised rosuvastatin (Crestor) levels by about 41%, which its label rates as not clinically significant. Tirzepatide (Mounjaro, Zepbound) has never been tested with a statin. The questions worth asking are about cholesterol targets and muscle aches, not about the combination itself.

What the studies measured: atorvastatin and rosuvastatin

GLP‑1 drugs slow the stomach, so every label warns they may change how tablets are absorbed. They do not act on the liver enzymes that clear most statins: the Wegovy label rates semaglutide’s potential to inhibit or induce CYP enzymes as very low, and the Zepbound label says the same of tirzepatide, as low.^[2][4] That matters because the statin interactions that cause real harm, such as atorvastatin with certain antibiotics or antifungals, run through those enzymes. A GLP‑1 works on a different lever.

The semaglutide injection study gave 26 healthy people a single 40 mg atorvastatin tablet before semaglutide and again once semaglutide 1 mg had reached steady state. The area under the curve, the measure of how much drug the body saw in total, came out at a ratio of 1.02. The peak fell 38%.^[8] The Ozempic label draws the conclusion that no dose adjustment is required.^[1] A later modeling analysis of the same data put the extra delay at about 67 minutes for atorvastatin, and judged it of no clinical relevance.^[11] Lilly’s dulaglutide study found atorvastatin’s total exposure down 21%, and still recommended no change in dose.^[10] That figure is also covered in GLP-1 drugs and your other medications.

Rosuvastatin went the other way with the semaglutide tablet. In 41 healthy people, exposure rose by 41% (90% confidence interval 24% to 60%), outside the range the trial had set for “no interaction”. The absorption enhancer in the tablet, SNAC, did not cause it on its own. The authors, all from the maker, called the increase small and not expected to matter.^[9] The semaglutide tablet label lists rosuvastatin among drugs with no clinically significant change.^[3] Nobody has tested rosuvastatin with the semaglutide injection or with tirzepatide.

Monitor the effects of oral medications concomitantly administered with WEGOVY.

— Wegovy prescribing information, section 7.2

That general sentence, and the tirzepatide labels’ equivalent naming warfarin as the example, are the only wording on these labels that could reach a statin.^[2][4] Neither names one.

Why a lower, later peak is not the worry for a statin

A statin lowers LDL cholesterol through steady daily dosing, not through a single spike. The Lipitor label shows this from another direction: taking it with food cuts the speed of absorption by about 25% and the total by about 9%, yet the LDL drop is the same either way.^[6] Crestor’s total exposure is not changed by food or by morning versus evening dosing.^[7] Our inference from those label findings: a GLP‑1 that blunts the peak without changing the total should not change what the statin does to cholesterol. No study has measured LDL response to a statin before and after a GLP‑1 is started.

The less reassuring evidence is indirect. A 2025 computer model, applying GLP‑1-style gut slowing to 1,000 virtual adults with obesity, predicted rosuvastatin exposure would rise 64%.^[12] That is a prediction, not a measurement. And Pfizer’s abandoned oral GLP‑1 pill, lotiglipron, raised rosuvastatin exposure up to 2.3-fold in a real study, alongside liver enzyme rises in some participants that the authors linked to the liver handling drugs less well.^[15] Lotiglipron is not semaglutide or tirzepatide. What it shows is that rosuvastatin is the statin more sensitive to a change in how the gut and liver handle it.

When to take each one

Neither statin label fixes a clock time or a meal rule: morning or night, fed or fasting, both are allowed.^[6][7] So there is no reason to move a statin to a different day from a weekly injection. The exception is the semaglutide tablet: its label wants a 30-minute gap after the tablet before any food, drink or other pill.^[3] A morning statin goes after that window. A statin taken in the evening avoids the question.

• Missed statin dose: the Lipitor label says to skip it and take the next scheduled dose; Crestor’s says not to take an extra one.^[6][7]
• Antacids for GLP‑1 heartburn: Crestor’s label asks for it to be taken at least two hours before an aluminum and magnesium hydroxide antacid.^[7]
• Vomiting: neither statin label says what to do if a tablet comes back up. Ask a pharmacist rather than doubling.

The heart trials were run on top of statins

This is the most useful fact on the page. Every large GLP‑1 heart-outcome trial enrolled people who were mostly on a statin already, and the benefit was measured against that background, not instead of it.

Sources: the Wegovy and semaglutide tablet labels,^[2][3] and the Mounjaro and Ozempic labels.^[5][1] SELECT’s participants started with an average LDL of 78.5 mg/dL, already low, and Wegovy still cut heart attacks, strokes and cardiovascular deaths by 20% in relative terms over a median of 41.8 months.^[2] In absolute terms the gap was 1.5 percentage points: 8.0% of people on placebo had an event against 6.5% on Wegovy. Crude arithmetic on those two numbers gives roughly 67 people treated for about three and a half years to prevent one event; how many people to treat to help one explains why a figure like that belongs to the trial’s population and no other.

The trials do not test what happens when someone stops a statin because they started a GLP‑1. Nobody was randomized to do that. Observational studies that report GLP‑1 users living far longer than non-users deserve the caution set out in when a hazard ratio is too good; the randomized evidence is the SELECT figure above, earned alongside a statin.

What a GLP-1 does to cholesterol

Less than many people expect. The labels report lipid changes from the main trials, and the pattern is the same for both drugs: a large fall in triglycerides, a small rise in HDL, and a small fall in LDL.

Sources: the Wegovy and Zepbound labels,^[2][4] and for Lipitor its dose-response table.^[6] The GLP‑1 labels note that these lipid results were not part of the trials’ formal testing hierarchy. Even so, the scale is clear. The lowest Lipitor dose lowers LDL roughly ten times as much as Wegovy or Zepbound did against placebo. A GLP‑1 does not do a statin’s job, and the heart benefit seen in SELECT came with very little LDL change. That benefit appears to come through other routes, which is a reason to keep both rather than to choose.

Should the statin dose change as the weight comes off?

Neither statin label ties the adult dose to body weight. Both set it by the LDL response and the person’s heart risk, and both say to check LDL as early as four weeks after starting and adjust if needed.^[6][7] We found no label or source recommending a lower statin dose because weight has fallen. What does change with a GLP‑1 is the lipid panel itself: triglycerides usually drop, and LDL may drift down a little. A repeat panel some months into treatment gives the prescriber real numbers to decide on, which is the label’s own method.

One label detail runs in the GLP‑1’s favor. Both statin labels warn that statins can nudge blood sugar and HbA1c up, and both answer with lifestyle advice that includes keeping a healthy body weight.^[6][7]

Muscle aches: the statin, the weight loss, or neither

This is where the two drugs get confused. Statins are blamed for aches far more often than they cause them. The largest analysis, pooling 19 blinded trials and 123,940 people, found muscle pain or weakness reported by 27.1% on a statin and 26.6% on placebo. In the first year the statin added 11 reports per 1,000 people a year; the authors calculated that only about one in 15 muscle complaints on a statin was actually caused by it, and after year one there was no clear excess.^[13] The excess was slightly larger on high-intensity regimens, meaning the top atorvastatin and rosuvastatin doses.^[13] The labels tell the same story: myalgia ran 3.5% on Lipitor against 3.1% on placebo, and in Crestor’s two-year METEOR trial, 12.7% against 12.1%.^[6][7]

GLP‑1 labels do not list muscle pain at all, and in the trials back and joint pain were about as common on placebo. What the drugs do cause is loss of lean tissue along with fat. GLP-1 drugs and joint pain, back pain and aches sets out the trial counts, and lean mass on a drug versus on a diet covers the muscle question. No study has looked at whether the two drugs together make aches more likely.

The statin labels list what does raise the risk of real muscle injury: age 65 or older, uncontrolled hypothyroidism, kidney impairment, certain other drugs, and higher statin doses; Crestor’s adds Asian ancestry.^[6][7] One item on that list connects to GLP‑1 side effects. Severe dehydration from vomiting or diarrhea can injure the kidneys, which the GLP‑1 labels warn about,^[2][4] and both statin labels name it.

Temporarily discontinue LIPITOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; …).

— Lipitor prescribing information, section 5.1 (the Crestor label uses the same words)

Severe hypovolemia means a serious loss of body fluid. A day of nausea does not qualify; days of vomiting with little fluid kept down might, and that call belongs to a clinician. A PubMed search found no published case of rhabdomyolysis, the dangerous form of muscle breakdown, in someone taking a GLP‑1 and a statin together. The one recent tirzepatide case involved a man who was not on a statin.^[14] More on kidneys and GLP‑1 dehydration is in GLP-1 drugs and your kidneys.

Stomach symptoms overlap too, though modestly on the statin side. On Lipitor, diarrhea was reported by 6.8% against 6.3% on placebo, and nausea by 4.0% against 3.5%.^[6] When nausea starts after a new GLP‑1 dose, the GLP‑1 is the likelier cause.

What to ask

1. When should my lipids be rechecked? A panel a few months into the GLP‑1 shows what changed, and the statin labels expect dose decisions to follow LDL results.
2. Is my statin dose still right for my risk? The answer depends on LDL and heart history, not on the scale.
3. On the semaglutide tablet: when should my statin go? After the 30-minute window, or in the evening.
4. What should I do if I am vomiting for more than a day? Ask in advance whether to hold the statin and when to call.
5. Are my aches worth checking? A creatine kinase blood test and a thyroid check can separate a statin problem from ordinary soreness.

Other entries in this series: blood thinners and a GLP-1, phentermine and a GLP-1 and levothyroxine and a GLP-1.